ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5018ometendo-5018Research ArticleСтатьиArticlesГиперC-пептидемия при метаболическом синдромеGiperC-peptidemiya pri metabolicheskom sindromeTerekhovaE N-TereshchenkoI V-20071509200743№3 (2007)2327Copyright © Terekhova E.N., Tereshchenko I.V., 20072007Terekhova E.N., Tereshchenko I.V.Terekhova E.N., Tereshchenko I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5018ReferencesОжирение: этиология, патогенез, клинические аспекты / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ООО «Медицинское информационное агенство», 2006. 456 с.Ожирение: этиология, патогенез, клинические аспекты / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ООО «Медицинское информационное агенство», 2006. 456 с.Araki A., Hosoi T., Orimo H., et al. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism. 2005;54(6):809-14.Araki A., Hosoi T., Orimo H., et al. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism. 2005;54(6):809-14.Chakrabarti S., Khan Z.A., Cukiernik M., et al. C-peptide and retinal microangiopathy in diabetes. Exp. Diabesity Res. 2004;5(1):91-6.Chakrabarti S., Khan Z.A., Cukiernik M., et al. C-peptide and retinal microangiopathy in diabetes. Exp. Diabesity Res. 2004;5(1):91-6.Fernqvist-Forbes E., Johanson B., Eriksson M. Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus. Acta Physiol Scand. 2001;172(3):159-65.Fernqvist-Forbes E., Johanson B., Eriksson M. Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus. Acta Physiol Scand. 2001;172(3):159-65.Haupt E., Benecke A., Haupt A., et al. The KID Study VI: diabetic complications and associated diseases in younger type 2 diabetics still per-forming a profession. Prevalence and correlation with duration of dia-betic state, BMI and C-peptide. Exp. Clin. Endocrinol. Diabetes. 1999;107(7):435-41.Haupt E., Benecke A., Haupt A., et al. The KID Study VI: diabetic complications and associated diseases in younger type 2 diabetics still per-forming a profession. Prevalence and correlation with duration of dia-betic state, BMI and C-peptide. Exp. Clin. Endocrinol. Diabetes. 1999;107(7):435-41.Jelenc M., Zemva A., Marn-Pernat, et al. Are insulin metabolism and night-time blood pressure related to left ventricular hypertrophy? Int. J. Cardiol. 1998;63(3):261-65.Jelenc M., Zemva A., Marn-Pernat, et al. Are insulin metabolism and night-time blood pressure related to left ventricular hypertrophy? Int. J. Cardiol. 1998;63(3):261-65.Lindenblatt N., Braun B., Menger M., et al. C-peptide exerts antithrom-botic effects that are repressed by insulin in normal and diabetic mice. Diabetologia. 2006;49(4):792-800.Lindenblatt N., Braun B., Menger M., et al. C-peptide exerts antithrom-botic effects that are repressed by insulin in normal and diabetic mice. Diabetologia. 2006;49(4):792-800.Marques R.G., Fontaine M.J., Rogers J. C-peptide: much more than a byproduct of insulin biosynthesis. Pancreas. 2004;29(3):231-38.Marques R.G., Fontaine M.J., Rogers J. C-peptide: much more than a byproduct of insulin biosynthesis. Pancreas. 2004;29(3):231-38.Marx N., Walcher D., Raichle C., et al. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and in-duces monocyte chemotaxis in vitro. Arterioscler. Tromb. Vasc. Biol. 2004;24(3):540-45.Marx N., Walcher D., Raichle C., et al. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and in-duces monocyte chemotaxis in vitro. Arterioscler. Tromb. Vasc. Biol. 2004;24(3):540-45.Polska E., Kolodjaschna J., Berisha F., et al. C-peptide does not affect ocular blood flow in patients with type 1 diabetes. Diabetes Care. 2006;29(9):2034-8.Polska E., Kolodjaschna J., Berisha F., et al. C-peptide does not affect ocular blood flow in patients with type 1 diabetes. Diabetes Care. 2006;29(9):2034-8.Rebsomen L., Pitel S., Boubred F., et al. C-peptide replacement improves weight gain and renal function in diabetes rats. Diabetes Metab. 2006;32(3):223-8.Rebsomen L., Pitel S., Boubred F., et al. C-peptide replacement improves weight gain and renal function in diabetes rats. Diabetes Metab. 2006;32(3):223-8.Tsimaratos M., Roger F., Chabardes D., et al. C-peptide stimulates Na+,K+-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia. 2003;46(1):124-31.Tsimaratos M., Roger F., Chabardes D., et al. C-peptide stimulates Na+,K+-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia. 2003;46(1):124-31.Wahren J. Ernst-Friedrich-Pfeiffer Memorial Lecture. New aspects of C-peptide physiology. Horm. Metab. Res. 1998;30(1):2-5.Wahren J. Ernst-Friedrich-Pfeiffer Memorial Lecture. New aspects of C-peptide physiology. Horm. Metab. Res. 1998;30(1):2-5.Wahren J., Ekberg K., Samnegard B., et al. C-peptide: a new potential in the treatment of diabetic nephropathy. Curr. Diab. Rep. 2001;1(3):261-66.Wahren J., Ekberg K., Samnegard B., et al. C-peptide: a new potential in the treatment of diabetic nephropathy. Curr. Diab. Rep. 2001;1(3):261-66.
The authors declare that there are no conflicts of interest present.